Document:

EXHIBIT 10.18

 

Reliant Pharmaceuticals, Inc.

110 Allen Road

Liberty Corner, NJ 
07938

908-580-1200

Fax: 908-542-9405

www.ReliantRx.com

 

July 28, 2006

 

HIGHLY
CONFIDENTIAL

 

Steve
Ketchum

Reliant
Pharmaceuticals, Inc.

 

Dear Steve:

 

With the very
successful launch of Omacor® and its promise of combination products with
expanded indications, our Company is entering a phase of significant growth. This
is due in large part to your individual efforts along with those of your
colleagues, and we take this opportunity to thank you for your extraordinary
commitment and very hard work.

 

We are very
pleased with the Company’s recent progress and recognize the importance of
sustained individual commitment in a cohesive organization in order to fully
exploit our opportunities going forward.

 

We will soon
have a new CEO to work with all of us to take Reliant to the next level of
growth and we expect that the new CEO will likely be in place by the end of
2006 or the beginning of 2007. We recognize that this process may be somewhat
distracting and we want to provide you with a one-time, special incentive to
assure sustained excellence, focus and cooperation within the organization during
the CEO succession process. I want you to know that the Board of Directors and
the Compensation Committee enthusiastically support the special incentive
program.

 

In general,
the special incentives will provide a retention bonus to special incentive
recipients who remain employed and in good standing with the Company through July
31, 2007 (or who are terminated by the Company without Cause or who leave the
Company with Good Reason). For special incentive recipients who do not
currently have a severance arrangement in place, severance protection will be
provided as well. The specific terms of your personalized special incentive are
set forth on Exhibit A attached to this letter. Formal documentation of
the terms described in Exhibit A will follow shortly.

 

 

As you would
imagine, the number of individuals in this program is very small, so it is a
condition of your actually receiving the special incentive that you not
share your participation or the details of your special incentive with anyone
else in the Company.

 

Please be
assured that I continue to be fully committed to the Company and its employees.
I look forward to working with you to realize Reliant’s full potential.

 

So, congratulations
for all of your hard work and being included in the special incentive program!  Staying together and committed, we will continue
to build Reliant into a company all will be proud to be a part of.

 

	
   

  	
  Sincerely,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Ernie Mario,
  Ph.D.

  
	
   

  	
  Chairman and
  CEO

  

 

 

Attachment

 

cc:  Mark Hoplamazian,

Chairman,
Compensation Committee of the Board of Directors

 

 

CONFIDENTIAL

 

EXHIBIT A

 

SPECIAL INCENTIVE

 

Steve Ketchum (“Participant”)

 

I. Retention
Bonus:

 

Bonus Amount:                                                                                                           $250,000.00.

 

Condition of
Payment:                                                                        Participant
must be employed and in good standing on July 31, 2007. Payment would be made
on August 1, 2007, subject to only to receipt from the participant of a general
release in the form to be attached to the formal documentation of the Retention
Bonus. No other performance or time based conditions on payment.

 

Payment
Acceleration:                                                                       If
the Participant is terminated by the Company prior to July 31, 2007 without
Cause (as defined below) or if the Participant leaves the Company with Good
Reason (as defined below), then the Participant would receive the retention
bonus amount on August 1, 2007, subject to only to receipt from the participant
of a general release in the form to be attached to the formal documentation of
the Retention Bonus.

 

II. Severance Benefit:1

 

Participant will be entitled to a severance benefit of one year’s
salary and medical benefit continuation if the Participant is terminated by the
Company without Cause or if the Participant leaves the Company for Good Reason
during the period from July 31, 2006 through the later of (a) the 12 month
anniversary of the start date of the new CEO and (b) January 31, 2008 (the “Benefit
Period”). The severance benefit described in this Section II is incremental
to (and not instead of) the Retention Bonus described above.

 

1  In the event that Participant’s pre-existing
entitlements are equal to or better than the cash severance benefit described
in this Section II (as determined by the Compensation Committee in consultation
with the Participant), the pre-existing terms would control.

 

 

III. Extension of Option Exercise Period:

 

In the event Participant is terminated without Cause (as defined below)
or leaves the Company with Good Reason (as defined below) during the Benefit Period,
the exercise period for Participant’s vested options on the date of termination
would be extended until (a) the later of (i) December 31 of the calendar year
in which the option otherwise would have expired, or (ii) the fifteenth day of
the third month following the date the options otherwise would have expired or
(b) a future fiscal year (i.e., 2008, 2009 or 2010) that needs to be agreed
upon currently in connection with formally documenting the benefits described
above and the option exercise extension (if triggered by early termination as
described above).2

 

IV. Defined Terms:

 

For the purposes of this Exhibit A and the formal documentation
of the terms of Exhibit A,  the
terms “Cause” and “Good Reason” will be defined as set forth below:

 

“Cause” means (a) in the event that Participant’s employment
agreement or employment offer letter includes a definition of “Cause”, then
such definition shall govern or (b) in all other cases, termination by the
Company of your employment with the Company due to (i) Participant’s commission
of an act of fraud or embezzlement against the Company or any affiliate
thereof, (ii) Participant’s breach of one or more of the following duties to
the Company:  (A) the duty of loyalty,
(B) the duty not to engage in self-dealing with respect to the Company’s
assets, properties or business opportunities, except as approved in writing by
the Board, (C) the duty of honesty or (D) any other fiduciary duty which you
owe to the Company, (iii) Participant’s conviction of (or a plea of nolo contendere in lieu thereof) for (A) a felony or (B) a
crime involving fraud, dishonesty or moral turpitude, (iv) intentional
misconduct with respect to Participant’s duties to the Company, including, but
not limited to, knowing and intentional violation of written policies of the
Company, including policies regarding confidential information and
non-competition, or specific directions of the Board or superior officers of
the Company, which policies or directives are neither illegal (or do not
involve illegal conduct) nor do they require you to violate reasonable business
ethical standards, or (v) Participant’s failure, after written notice from the
Company, to render services to the Company in accordance with Participant’s
employment duties, which failure is not cured within 10 days of receipt of such
notice.

 

“Good Reason” means (a) in the event that Participant’s
employment agreement or employment offer letter includes a definition of “Good
Reason”, then such definition shall govern or (b) in all other cases, (i) a
material reduction in Participant’s base salary and benefits from the levels
provided as of July 31, 2006, (ii) a material reduction of Participant’s duties
and responsibilities from those in

 

2  Please note that these time periods are
driven by 409A (deferred compensation rules) considerations.

 

 

effect as of July 31, 2006, or (iii) without Participant’s consent,
Participant is relocated for at least six (6) months to a location more than
seventy-five (75) miles from your current principal place of employment.EXHIBIT 10.19

 

RELIANT PHARMACEUTICALS, LLC

 

EQUITY INCENTIVE PLAN

 

RESTRICTED UNIT AGREEMENT

 

Unless
otherwise specified herein, all capitalized terms shall have the same meanings
as set forth in the Reliant Pharmaceuticals, LLC Equity Incentive Plan (the “Plan”).

 

I.                                        NOTICE OF GRANT

 

Ernest Mario

 

                                                  

                                                  

                                                  

                                                  

 

You (“Participant”) are hereby granted Class One Common Units (the
“Units”) in the Company, subject to the
terms and conditions of the Plan and this Restricted Unit Agreement. The terms
of your grant are set forth below:  

 

	
  Date of Grant:

  	
   

  	
  April 28, 2003

  
	
   

  	
   

  	
   

  
	
  Grant Price per Unit:

  	
   

  	
  N/A

  
	
   

  	
   

  	
   

  
	
  Units Granted:

  	
   

  	
  57,750

  

 

All of the Units subject to this Restricted Unit
Agreement (the “Restricted Units”)
shall be 100% vested and non-forfeitable on the Date of Grant, subject only to
the terms of this Agreement.

 

II.                                    AGREEMENT

 

1.                                       Grant
of Restricted Units. The Company hereby grants to the Participant right to
purchase the number of Restricted Units set forth in the Notice of Grant. Participant
has ten (10) days from the Date of Grant set forth in the Notice of Grant to exercise
his/her right to purchase the Restricted Units and deliver the Purchase Price. If
Participant does not so exercise his/her right to purchase the Restricted
Units, then this Agreement shall be null and void and Participant shall have no
further rights in the Restricted Units. On the Date of Grant, Participant shall
deliver to the Company his Investment Representation Statement in the form
attached hereto as Exhibit A.

 

 

Notwithstanding
anything to the contrary anywhere else in this Restricted Unit Agreement, this
grant of Restricted Units is subject to the terms, definitions and provisions
of the Plan and the LLC Agreement which are incorporated herein by reference.

 

2.                                       [RESERVED]

 

3.                                       Rights
and Obligations as a Member. The Participant shall have all rights of a
Common Holder with respect to the Restricted Units as provided in the LLC
Agreement. By executing this Agreement, Participant, without further action on
his or her part, agrees to be deemed a party to, a signatory of and bound by
the LLC Agreement, and the Restricted Units shall be subject to such rights and
restrictions as contained therein. Participant shall enjoy rights as a Common
Holder and shall be subject to all of the limitations, restrictions and
obligations contained in the LLC Agreement as a Common Holder, until such time
as Holder disposes of the Units or the Company and/or its assignee(s) exercises
the Right of First Refusal provided in this Agreement or otherwise in the LLC
Agreement. Upon such exercise, Participant shall have no further rights as a
holder of the Units so purchased except the right to receive payment for the
Units so purchased in accordance with the provisions of this Agreement and the
LLC Agreement. This Agreement shall not affect in any way the ownership, voting
rights or other rights or duties of Participant, except as specifically
provided herein.

 

4.                                       Participant’s
Rights to Transfer Units.

 

(a)                                  Limitations
on Transfer. Participant may transfer the Restricted Units (or any
securities into which such Units may be converted), subject to the restrictions
contained in this Section 4 and the LLC Agreement; provided however no Units
may be transferred (i) to a direct competitor of the Company as determined
by the Board or (ii) for consideration other than cash.

 

(b)                                 Company’s
Right of First Refusal. Before any Restricted Units (or any securities into
which such Units may be converted) held by Participant or any permitted
transferee (each, a “Holder”) may be
sold, pledged, assigned, hypothecated, transferred or otherwise disposed of
(including transfer by gift or operation of law, collectively a “Transfer” or “Transferred”),
the Company or its assignee(s) shall have a right of first refusal to purchase
the Restricted Units on the terms and conditions set forth in this Section (the
“Right of First Refusal”).

 

(i)                                     Notice
of Proposed Transfer. The Holder of the Restricted Units shall deliver to
the Company a written notice (the “Notice”)
stating:  (i) the Holder’s bona fide
intention to sell or otherwise Transfer such Units; (ii) the name of each
proposed transferee (“Proposed Transferee”);
(iii) the Restricted Units to be Transferred to each Proposed Transferee;
and (iv) the bona fide cash price for which the Holder proposes to
Transfer the Units (the “Offered Price”),
and the Holder shall offer the Units at the Offered Price to the Company or its
assignee(s).

 

(ii)                                  Exercise
of Right of First Refusal. Within thirty (30) days after receipt of the
Notice, the Company and/or its assignee(s) may elect in writing to purchase
all, but

 

2

 

not less than all, of the Units proposed to be Transferred to any one
or more of the Proposed Transferees. The purchase price will be determined in
accordance with subsection (iii) below.

 

(iii)                               Purchase Price. The
purchase price (“Purchase Price”) for the
Restricted Units repurchased under this Section shall be the Offered Price.

 

(iv)                              Payment.
Payment of the Purchase Price shall be made, at the option of the Company or
its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of
repurchase by an assignee, to the assignee), or by any combination thereof
within thirty (30) days after receipt of the Notice or in the manner and at the
times set forth in the Notice.

 

(v)                                 Holder’s
Right to Transfer. If all of the Restricted Units proposed in the Notice to
be transferred to a given Proposed Transferee are not purchased by the Company
and/or its assignee(s) as provided in this Section, then subject to any rights
of first refusal and other restrictions on transfer contained in the LLC
Agreement, the Holder may sell or otherwise Transfer such Units to that
Proposed Transferee at the Offered Price or at a higher price, provided that
such sale or other Transfer is consummated within one hundred twenty (120) days
after the date of the Notice and provided further that any such sale or other
Transfer is effected in accordance with any applicable securities laws and the
Proposed Transferee agrees in writing that the provisions of this Section and
the Restricted Unit Agreement, as applicable, shall continue to apply to the
Restricted Units in the hands of such Proposed Transferee. If the Units
described in the Notice are not Transferred to the Proposed Transferee within
such period, a new Notice shall be given to the Company, and the Company and/or
its assignees shall again be offered the Right of First Refusal as provided
herein before any Restricted Units held by the Holder may be sold or otherwise
Transferred. The Company’s Right of First Refusal as contained herein shall be
in addition to and arise prior to any rights of first refusal contained in the
LLC Agreement.

 

(c)                                  Exception
for Certain Family Transfers. Anything to the contrary contained in this
Section notwithstanding, the Transfer of any or all of the Restricted Units
during the Participant’s lifetime or on the Participant’s death by will or
intestacy to the Participant’s Immediate Family shall be exempt from the Right of
First Refusal. Participant’s Immediate Family includes Participant’s and
Participant’s Immediate Family’s trusts, foundations, partnerships and other
family entities. In such case, the transferee or other recipient shall receive
and hold the Restricted Units so Transferred subject to the provisions of this
Section, Section 5 and the Restricted Unit Agreement, as applicable, and there
shall be no further Transfer of such Restricted Units except in accordance with
the terms of this Section.

 

(d)                                 Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to
all Restricted Units (and any securities of the Company in which such
Restricted Units may be converted) ninety (90) days after a sale of common
stock of the Company to the general public pursuant to a registration statement
filed with and declared effective by the Securities and Exchange Commission
under the Securities Act of 1933, as amended (a “Public
Offering”).

 

3

 

5.                                       Company
Call Right.

 

(a)                                  If
Participant ceases to be a Service Provider for any reason, the Company shall
have the right to purchase any or all of the Restricted Units (or any
securities into which such Units may be converted) then owned by the Holder of
such Restricted Units at a price equal to the Fair Market Value of the
Restricted Units on the date on which the Participant ceases to be a Service
Provider (the “Call Right”).

 

(b)                                 The
Company may exercise the Company Call Right by delivering personally or by
registered mail to Holder within ninety (90) days of the date on which
Participant ceases to be a Service Provider, a notice in writing indicating the
Company’s intention to exercise the Company Call Right and setting forth a date
for closing not later than thirty (30) days from the mailing of such notice. The
closing shall take place at the Company’s office.

 

(c)                                  At
its option, the Company may elect to make payment for the Restricted Units to a
bank selected by the Company. The Company shall avail itself of this option by
a notice in writing to Holder stating the name and address of the bank, date of
closing, and waiving the closing at the Company’s office.

 

(d)                                 If
the Company does not elect to exercise the Company Call Right conferred above
by giving the requisite notice within ninety (90) days following the date on
which Participant ceases to be a Service Provider, the Company Call Right shall
terminate.

 

(e)                                  The
Company Call Right shall terminate as to all Units (or any securities into
which such Units may be converted) ninety (90) days after a Public Offering.

 

6.                                       Lock-Up
Period. Participant hereby agrees that if so requested by the Company (any
successor thereto) or any representative of the underwriters (the “Managing Underwriter”) in connection with any registration
of the offering of any securities of the Company under the Securities Act of
1933, as amended (the “Securities Act”),
Participant shall not sell or otherwise transfer any Units (or any securities
of the Company in which such Units may be converted) or other securities of the
Company during the 180-day period (or such longer period as may be requested in
writing by the Managing Underwriter and agreed to in writing by the Company)
(the “Market Standoff Period”) following the
effective date of a registration statement of the Company filed under the
Securities Act; provided, however, that such
restriction shall apply only to the first registration statement of the Company
to become effective under the Securities Act that includes securities to be
sold on behalf of the Company to the public in an underwritten public offering
under the Securities Act. The Company may impose stop-transfer instructions
with respect to securities subject to the foregoing restrictions until the end
of such Market Standoff Period.

 

7.                                       Refusal
to Transfer. The Company shall not be required (i) to transfer on its
books any Restricted Units that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or the LLC Agreement or
(ii) to treat as owner of such Restricted Units or to accord the right to
vote or pay dividends to any Participant or other transferee to whom such
Restricted Units shall have been so transferred.

 

4

 

8.                                       Successors
and Assigns. The Company may assign any of its rights under this Agreement
to single or multiple assignees, and this Agreement shall inure to the benefit
of the successors and assigns of the Company. Subject to the restrictions on
transfer herein set forth, this Agreement shall be binding upon Participant and
his or her heirs, executors, administrators, successors and assigns.

 

9.                                       Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted
by Participant or by the Company forthwith to the Company’s Board of Managers
or committee thereof that is responsible for the administration of the Plan
(the “Administrator”), which shall review
such dispute at its next regular meeting. The resolution of such a dispute by
the Administrator shall be final and binding on the Company and on Participant.

 

10.                                 Notices.
Any notice required or permitted hereunder shall be given in writing and shall
be deemed effectively given upon personal delivery or upon deposit in the
United States mail by certified mail, with postage and fees prepaid, addressed
to the other party at its address as shown below beneath its signature, or to
such other address as such party may designate in writing from time to time to
the other party. Participant further agrees to notify the Company upon any
change in the residence address indicated below.

 

11.                                 Further
Instruments. The parties agree to execute such further instruments and to
take such further action as may be reasonably necessary to carry out the
purposes and intent of this Agreement.

 

12.                                 Entire
Agreement. The Plan and LLC Agreement are incorporated herein by reference.
This Agreement, the Plan, the Investment Representation Statement and the LLC
Agreement constitute the entire agreement of the parties and supersede in their
entirety all prior undertakings and agreements of the Company and Participant
with respect to the subject matter hereof.

 

13.                                 Spousal
Consent. As a further condition to the Company’s and Participant’s
obligations under this Agreement, the spouse of the Participant, if any, shall
execute and deliver to the Company the Consent of Spouse attached hereto as Exhibit B.

 

14.                                 Governing
Law; Severability. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware excluding that body of law
pertaining to conflicts of law. Should any provision of this Agreement be
determined by a court of law to be illegal or unenforceable, the other
provisions shall nevertheless remain effective and shall remain enforceable.

 

15.                                 No
Right to Employment. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT
NOTHING IN THIS AGREEMENT, NOR IN THE COMPANY’S EQUITY INCENTIVE PLAN WHICH IS
INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON PARTICIPANT ANY RIGHT WITH
RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL
IT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE

 

5

 

COMPANY’S RIGHT TO TERMINATE PARTICIPANT’S EMPLOYMENT OR CONSULTANCY AT
ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE.

 

16.                                 Representations
of Participant. Participant acknowledges that he or she has received, read
and understood the Plan, the LLC Agreement, this Restricted Unit Agreement and
is familiar with their terms and provisions. Participant hereby agrees to
accept as binding, conclusive and final all decisions or interpretations of the
Committee upon any questions arising under this Agreement.

 

IN
WITNESS WHEREOF, this Agreement is deemed made as of the date first set forth
above.

 

	
   

  	
  RELIANT PHARMACEUTICALS,
  LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  PARTICIPANT

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Ernest Mario

  
					

 

6

 

EXHIBIT A

 

INVESTMENT REPRESENTATION STATEMENT

 

	
  PARTICIPANT

  	
  :

  	
  ERNEST MARIO

  
	
   

  	
   

  	
   

  
	
  COMPANY

  	
  :

  	
  RELIANT
  PHARMACEUTICALS, LLC

  
	
   

  	
   

  	
   

  
	
  SECURITY

  	
  :

  	
  CLASS ONE COMMON UNITS

  
	
   

  	
   

  	
   

  
	
  AMOUNT

  	
  :

  	
  57,750

  
	
   

  	
   

  	
   

  
	
  DATE

  	
  :

  	
  April 28, 2003

  

 

In
connection with the purchase of the above-listed Securities, the undersigned
Participant represents to the Company the following:

 

(a)                                  Participant
is aware of the Company’s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and
knowledgeable decision to acquire the Securities. Participant has received and
read the financial information provided by the Company and has had an
opportunity to discuss the Company’s business, management and financial affairs
with the managers, officers and other management personnel of the Company. Participant
has also had the opportunity to ask questions of and receive answers from, the
Company and its management regarding the risks, terms and conditions of this
investment.

 

(b)                                 Participant
(i) has such knowledge and experience in financial and business matters
that it is capable of evaluating the merits and risks of its investment in
these Securities, (ii) is able to bear the complete loss of his investment
in these Securities, and (iii) is an “accredited investor” as that term is
defined in Rule 501(a)(3) under the Securities Act of 1933, as amended (the “Securities Act”).

 

(c)                                  Participant
is acquiring these Securities for investment purposes for Participant’s own
account only and not with a view to distributing or resale of all or any part
thereof in any transaction which would constitute a “distribution”
within the meaning of the Securities Act. Participant acknowledges that none of
the Securities have been registered under the Securities Act and, except as may
be specifically agreed to by the Company, the Company is under no obligation to
file a registration statement with the Securities and Exchange Commission with
respect to all or any part of such Securities.

 

Participant
acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have not
been registered under the Securities Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide
nature of Participant’s investment intent as expressed herein. In this
connection, Participant understands that, in the view of the Securities and
Exchange Commission, the statutory basis for such exemption may be unavailable
if Participant’s representation was predicated solely upon a present intention
to hold these Securities for the

 

1

 

minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the
market price of the Securities, or for a period of one year or any other fixed
period in the future. Participant further understands that the Securities must
be held indefinitely unless they are subsequently registered under the
Securities Act or an exemption from such registration is available. Participant
has been advised or is aware of the provisions of Rule 144 promulgated under the
Securities Act, which permits limited resale of securities purchased in a
private placement subject to the satisfaction of certain conditions, including,
among other things:  the availability of
certain current public information about the Company, the resale occurring not
less than one year after a party has purchased and paid for the security to be
sold, the sale being through an unsolicited “broker’s
transaction” or in transactions directly with a market maker (as
said term is defined under the Securities Exchange Act of 1934, as amended) and
the number of shares being sold during any three-month period not exceeding
specified limitations.

 

(d)                                 Participant
is an “Accredited Investor” as defined in Rule 501 issued under the Securities
Act by the fact that Participant either (1) is an executive officer of the
Company, (2) has an individual net worth or joint net worth with his or her
spouse in excess of $1,000,000, or (3) has individual income in excess of
$200,000, or joint income with his or her spouse in excess of $300,000 in each
of the two most recent years and has a reasonable expectation of reaching the
same income level in the current year.

 

	
   

  	
  Signature of
  Participant:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Ernest Mario

  
	
   

  	
   

  
	
   

  	
  Date:

  	
   

  	
   

  
				

 

2

 

EXHIBIT B

 

CONSENT OF SPOUSE

 

I,                          ,
spouse of Ernest Mario have read and approve the foregoing Restricted Unit
Agreement. In consideration of granting of the right to my spouse to purchase
Class One Common Units of Reliant Pharmaceuticals, LLC as set forth in the
Agreement, I hereby appoint my spouse as my attorney-in-fact in respect to the
exercise of any rights under the Agreement and agree to be bound by the
provisions of the Agreement insofar as I may have any rights in said Agreement
or any shares issued pursuant thereto under the community property laws or
similar laws relating to marital property in effect in the state of our
residence as of the date of the signing of the foregoing Agreement.

 

 

	
  Dated:                           ,
          

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Printed name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]